Breaking News Instant updates and real-time market news.

MYL

Mylan

$38.15

-0.5 (-1.29%)

, VRX

Valeant

$13.46

-0.0103 (-0.08%)

10:20
05/19/17
05/19
10:20
05/19/17
10:20

USPTO sides with Mylan in challenge of Salix patent

The USPTO's Patent Trial and Appeal Board determined that claims 1 and 16 of the 8,865,688 patent owned by Dr. Falk Pharma GmbH are unpatentable. The patent relates to Salix Pharmaceuticals' Ulcerative Colitis treatment. Salix is owned by Valeant (VRX). The inter partes review of the patent was instituted following a challenge made by Mylan Pharmaceuticals (MYL).

MYL

Mylan

$38.15

-0.5 (-1.29%)

VRX

Valeant

$13.46

-0.0103 (-0.08%)

  • 19

    May

  • 22

    May

  • 06

    Jun

  • 24

    Aug

  • 03

    Sep

  • 09

    Oct

MYL Mylan
$38.15

-0.5 (-1.29%)

05/10/17
WELS
05/10/17
NO CHANGE
Target $40
WELS
Market Perform
Mylan deals masking 'weak' organic sales, says Wells Fargo
Wells Fargo analyst David Maris believes Mylan's deals are masking the company's contracting organic growth. When excluding deals, Mylan's total third party sales declined approximately 4% in Q1, with North American Sales down 11%, Europe down 1% and Rest of World up 11%, Maris tells investors in a post-earnings research note. He believes Mylan this morning reported an essentially in-line quarter on earnings, but that organic sales were "weak," particularly in North America. Maris has a Market Perform rating on Mylan with a $40 price target.
05/01/17
BMOC
05/01/17
INITIATION
Target $50
BMOC
Outperform
Mylan initiated with an Outperform at BMO Capital
BMO Capital analyst GaryNachman started Mylan with an Outperform rating and $50 price target. The company is one of the best positioned to navigate through the challenging generic trends over the longer term, the analyst argues.
04/25/17
WELS
04/25/17
NO CHANGE
WELS
Novartis results highlight tough pricing environment, says Wells Fargo
This morning's Q1 results from Novartis' (NVS) Sandoz division highlight the difficult U.S. generic price environment, Wells Fargo analyst David Maris tells investors in a research note. Sandoz experienced pricing erosion of 8% in the quarter, which represents the largest negative impact from pricing in recent quarters, Maris writes. He expects the negative U.S. pricing environment to impact including Mallinckrodt (MNK), Teva (TEVA), Mylan (MYL) and Perrigo (PRGO). Maris remains cautious on the pricing environment for generics.
04/11/17
WELS
04/11/17
NO CHANGE
WELS
Market Perform
Wells unsure of risk to Mylan from FDA warning letter
Wells Fargo analyst David Maris says he does not know what products, if any, are manufactured at Mylan's India-based plant that received the warning letter from the FDA. As such, the letter may have little or no immediate commercial risk, Maris tells investors in an intraday research note. The analyst questions whether the FDA will stop letting drugs from this facility into the U.S. He adds that to him, "nothing is more critical for a brand or generic drug company than being able to ensure that its products are safe and effective." Maris keeps a Market Perform rating on Mylan.
VRX Valeant
$13.46

-0.0103 (-0.08%)

05/19/17
DBAB
05/19/17
NO CHANGE
Target $18
DBAB
Hold
Deutsche Bank 'warming up' to Valeant story
In a research note titled "Warming up to VRX," Deutsche Bank analyst Gregg Gilbert says that while Valeant Pharmaceuticals is "not out of the woods," the worst fears may be subsiding. The analyst continues to view the company's near-term setup as "encouraging." Valeant's 2017 outlook seems reachable, asset sales in the near- and medium-term seem likely, and the recent refinancing provided more time and flexibility for the company to deal with its issues, Gilbert tells investors. He also believes the worst case for Xifaxan of near-term generic competition "seems to be off the table for now." The analyst keeps a Hold rating on Valeant with an $18 price target. The drugmaker closed yesterday up 22c to $13.47.
05/11/17
WELS
05/11/17
NO CHANGE
Target $9
WELS
Underperform
Valeant estimates reduced on weakening fundamentals at Wells Fargo
Wells Fargo analyst David Maris said the reaction to Valeant's guidance is too positive and notes leverage has increased, most businesses missed his forecasts, and the increase in EBITDA guidance was due to changes in how it accounts for foreign exchange. The analyst lowered estimates and reiterated his Underperform rating given the company's deteriorating fundamentals, adding that he expects the recent share strength to be temporary. However, he increased his price target on the shares to $9 from $8, noting Valeant's Q1 showed a "dramatic decline" in working capital.
05/09/17
JPMS
05/09/17
NO CHANGE
JPMS
Neutral
Valeant's road to recovery remains long, says JPMorgan
JPMorgan analyst Chris Schott finds today's rally in Valeant Pharmaceuticals unsurprising as EBITDA guidance was raised following significant cuts over the past year. That said, the analyst continues to see a "long road to recovery for the story." He keeps a Neutral rating on the shares. Valeant is up 18%, or $1.79, to $11.50 in midday trading.
05/09/17
WELS
05/09/17
NO CHANGE
WELS
Underperform
Valeant key products continue to underperform, says Wells Fargo
Following the company's Q1 results, Wells Fargo analyst David Maris says Valeant Pharmaceuticals' key products continue to underperform. Valeant's decision to highlight in its press release the EBITDA raise of 1.3% is understandable, as this is better than the recent trend, but the $50M raise is relative to approximately $28.9B of total debt, Maris tells investors in a research note. Key products and areas such as Xifaxan and Bausch + Lomb continue to underperform, the analyst contends. He keeps an Underperform rating on Valeant with an $8 price target. The stock in morning trading is up 15%, or $1.48, to $11.19.

TODAY'S FREE FLY STORIES

FIT

Fitbit

$5.61

-0.15 (-2.60%)

08:45
07/24/17
07/24
08:45
07/24/17
08:45
Options
Largest borrow rate increases among liquid names »

Latest data shows the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

SPI

SPI Energy

$0.54

-0.047 (-8.01%)

08:44
07/24/17
07/24
08:44
07/24/17
08:44
Hot Stocks
SPI Energy says Nasdaq grants request to extend stay of suspension in trading »

SPI Energy announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBIO

iBio

$0.32

-0.006 (-1.82%)

08:43
07/24/17
07/24
08:43
07/24/17
08:43
Hot Stocks
iBio enters into stock purchase agreement for up to $16M with LPC »

iBio announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYTX

Cytori Therapeutics

$1.11

-0.01 (-0.89%)

08:43
07/24/17
07/24
08:43
07/24/17
08:43
Conference/Events
Cytori Therapeutics to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BOH

Bank of Hawaii

$81.45

-0.52 (-0.63%)

08:42
07/24/17
07/24
08:42
07/24/17
08:42
Earnings
Bank of Hawaii reports Q2 EPS $1.05, consensus $1.03 »

Loan and lease balances…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

JCP

J.C. Penney

$5.08

0.08 (1.60%)

, AAPL

Apple

$150.27

-0.07 (-0.05%)

08:40
07/24/17
07/24
08:40
07/24/17
08:40
Hot Stocks
J.C. Penney now accepts Apple Pay at all stores »

JCPenney (JCP) has rolled…

JCP

J.C. Penney

$5.08

0.08 (1.60%)

AAPL

Apple

$150.27

-0.07 (-0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

WWD

Woodward

$68.55

-0.87 (-1.25%)

08:39
07/24/17
07/24
08:39
07/24/17
08:39
Conference/Events
Woodward management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 31

    Jul

SILC

Silicom

$51.37

0.96 (1.90%)

08:38
07/24/17
07/24
08:38
07/24/17
08:38
Conference/Events
Silicom management to meet with Needham »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 31

    Jul

  • 01

    Aug

OTIV

On Track Innovations

$1.47

0.025 (1.74%)

08:38
07/24/17
07/24
08:38
07/24/17
08:38
Hot Stocks
On Track Innovations' Uno-8 contactless reader granted EMVCo Modular approval »

On Track Innovations…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Aug

FNJN

Finjan Holdings

08:38
07/24/17
07/24
08:38
07/24/17
08:38
Hot Stocks
Finjan Holdings says oral arguments to be heard at Court of Appeals on Sep. 8 »

Finjan Holdings (FNJN),…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

POL

PolyOne

$38.46

-0.18 (-0.47%)

08:37
07/24/17
07/24
08:37
07/24/17
08:37
Conference/Events
PolyOne management to meet with Northcoast »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 31

    Jul

  • 01

    Aug

ARNC

Arconic

$25.21

0.46 (1.86%)

08:37
07/24/17
07/24
08:37
07/24/17
08:37
Earnings
Arconic sees FY17 EPS $1.15-$1.20, consensus $1.16 »

The company adjusted 2017…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

HIFR

InfraREIT

$19.90

0.2 (1.02%)

08:37
07/24/17
07/24
08:37
07/24/17
08:37
Hot Stocks
Breaking Hot Stocks news story on InfraREIT 

InfraREIT trading resumes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

SLB

Schlumberger

$66.53

-0.49 (-0.73%)

08:36
07/24/17
07/24
08:36
07/24/17
08:36
Recommendations
Schlumberger analyst commentary  »

Schlumberger price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MED

Medifast

$42.11

0.28 (0.67%)

08:36
07/24/17
07/24
08:36
07/24/17
08:36
Hot Stocks
Medifast: Take Shape For Life rebrands to OPTAVIA »

Medifast announced its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

P

Pandora

$9.47

0.33 (3.61%)

, AAPL

Apple

$150.27

-0.07 (-0.05%)

08:36
07/24/17
07/24
08:36
07/24/17
08:36
Periodicals
Spotify near new licensing pact with Warner Music, Reuters reports »

Spotify and Warner Music…

P

Pandora

$9.47

0.33 (3.61%)

AAPL

Apple

$150.27

-0.07 (-0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 01

    Aug

  • 08

    Aug

  • 09

    Aug

  • 05

    Sep

HIFR

InfraREIT

$19.90

0.2 (1.02%)

08:35
07/24/17
07/24
08:35
07/24/17
08:35
Hot Stocks
InfraREIT announces agreement regarding dismissal of pending rate case »

InfraREIT announced an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

DMPI

DelMar Pharmaceuticals

$2.08

0.11 (5.58%)

08:34
07/24/17
07/24
08:34
07/24/17
08:34
Hot Stocks
DelMar Pharmaceuticals: HGRAC approves safety, efficacy study of VAL-083 »

DelMar Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVCR

Novocure

08:34
07/24/17
07/24
08:34
07/24/17
08:34
Conference/Events
Novocure management to meet with JMP Securities »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 31

    Jul

ALV

Autoliv

$106.78

-9.11 (-7.86%)

08:34
07/24/17
07/24
08:34
07/24/17
08:34
Recommendations
Autoliv analyst commentary  »

Autoliv has reached…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Sep

LMAT

LeMaitre

$28.31

-0.89 (-3.05%)

08:33
07/24/17
07/24
08:33
07/24/17
08:33
Conference/Events
LeMaitre management to meet with Craig Hallum »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 31

    Jul

ARNC

Arconic

$25.21

0.46 (1.86%)

08:33
07/24/17
07/24
08:33
07/24/17
08:33
Earnings
Arconic reports Q2 EPS ex-items 32c, consensus 26c »

Reports Q2 revenue $3.3B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

WU

Western Union

$19.09

0.01 (0.05%)

, BP

BP

$34.68

-0.42 (-1.20%)

08:33
07/24/17
07/24
08:33
07/24/17
08:33
Hot Stocks
Western Union announces agreement with BP Australia »

The Western Union Company…

WU

Western Union

$19.09

0.01 (0.05%)

BP

BP

$34.68

-0.42 (-1.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

GRA

W.R. Grace

$72.17

1.12 (1.58%)

08:33
07/24/17
07/24
08:33
07/24/17
08:33
Conference/Events
W.R. Grace management to meet with Seaport Global »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 31

    Jul

  • 01

    Aug

PFE

Pfizer

$33.48

-0.06 (-0.18%)

08:32
07/24/17
07/24
08:32
07/24/17
08:32
Hot Stocks
Pfizer says Reflections B7391003 study met primary objective »

Pfizer announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

  • 02

    Aug

  • 03

    Aug

  • 27

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.